close_game
close_game

serum institute of india

PAGE 3

Latest from serum institute of india

Cervical cancer prevention: Not many takers for HPV vaccine at Chandigarh’s PGIMER

Cervavac was developed by Serum Institute Of India (SII) in collaboration with central government’s department of biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC), along with the Bill and Melinda Gates Foundation

Sharing data, doctors at PGIMER’s gynaecological department and Advance Paediatric Centre attributed the low uptake to lack of awareness, the vaccine’s hefty price tag and the fact that the vaccine is not included in the national immunisation programme. (iStock)
Published on Apr 16, 2025 10:36 AM IST
ByPriyanka Thakur, Chandigarh

Adar Poonawalla speaks out on work-life balance: 'Can't go beyond 8-9 hours'

The Serum CEO said that meeting people and building relationships, for charity or networking purposes, is as crucial as office hours.

Adar Poonawalla said that just working in office from Monday to Sunday is a
Updated on Jan 23, 2025 12:43 PM IST

Ajit Pawar visits SPPU, takes review of various works

The deputy chief minister said that not a single university in the country is in the list of top 200 universities in the world. He assured that the state government will provide support to the university to get its name in the global list

Pawar visited the university at 7 am and met officials, including SPPU vice-chancellor professor Suresh Gosavi; pro-vice-chancellor professor Parag Kalkar among others. (HT PHOTO)
Updated on Jan 10, 2025 08:12 AM IST

Health Talk: Why an India-made Chikungunya vaccine is good news

Serum Institute of India will manufacture Valneva's anti-Chikungunya vaccine for India and select Asian markets, addressing a major public health issue.

Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes that causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash (Representative image)
Updated on Dec 21, 2024 01:18 PM IST

SII to manufacture French firm’s vaccine for chikungunya

Serum Institute of India will manufacture a chikungunya vaccine for the Indian market and a few other Asian countries under a licensing agreement between the company and France-based Valneva SE’s

SII to manufacture French firm’s vaccine for chikungunya
Updated on Dec 20, 2024 07:10 AM IST
By, New Delhi
Story Saved
Live Score
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, May 06, 2025
Follow Us On